ARPC5L

Across TCGA pan-cancer cohorts, ARPC5L mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARPC5L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARPC5L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARPC5L is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where ARPC5L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARPC5L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.416	<.001	11	view →
COAD	Male	II,III,IV	−0.203	<.001	11	view →
LSCC	Male	II,III,IV	+0.364	<.001	9	view →
LUAD	Female	All	+0.348	<.001	8	view →
HNSC	Male	All	−0.177	.001	5	view →
OV	All	All	+0.304	.040	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARPC5L–CCRCC

Open the CCRCC breakdown →